KUALA LUMPUR, Oct 29 -- Crown Bioscience has entered into a strategic collaboration with NEXT Oncology to provide new clinically-relevant PDX models for preclinical drug development.
The agreement establishes CrownBio as the exclusive global commercialisation partner for all primary tumour PDX models generated by NEXT Oncology over the next five years.
These models will be developed from patients who participate in early clinical trials, and incorporate the latest targeted therapies and immunotherapies, with a particular focus on resistance mechanisms.
The partnership will initially provide 350 PDX models to be established over the period, with each model paired with critical characterisation data and associated patient clinical history.
As part of the agreement, NEXT Oncology will leverage CrownBio’s unrivalled expertise in the development of PDX models from patient tissues, its systems biology platform as well as associated biomarkers and companion diagnostic discovery capability.
The initial models from this agreement are expected to be ready for client studies by mid-2020.
-- BERNAMA
No comments:
Post a Comment